Structure via PubChem · Public domain (PubChem)
empagliflozin
Sign in to saveAlso known as BI 10773, BI-10773, BI10773, (1S)-1,5-anhydro-1-C-{4-chloro-3-((4-{((3S)-oxolan-3-yl)oxy}phenyl)methyl)phenyl}-D-glucitol, 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene, (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol
Empagliflozin, sold under the brand name Jardiance ( ), among others, is an antidiabetic medication used to improve glucose control in people with type2 diabetes and/or for patients with established heart failure with reduced ejection fraction (HFrEF). Studies have shown great benefits for heart failure (HF) outcomes and decreased hospitalisations. It is taken by mouth.
Chemical data
- Formula
- C23H27ClO7
- Molecular weight
- 450.9 g/mol
- IUPAC name
- (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
- SMILES
- C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
- InChIKey
- OBWASQILIWPZMG-QZMOQZSNSA-N
- XLogP
- 2
- Polar surface area
- 109 Ų
- H-bond donors
- 4
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Research
4,503 papers- Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway.Redox biology · 2022
- Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.Advances in therapy · 2024
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.The New England journal of medicine · 2016
- Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis.Cardiovascular diabetology · 2022
- Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.Diabetes care · 2015
via PubMed
~18 min read
Encyclopedic overview
21 sectionsContents
- Medical uses
- Diabetes
- Chronic Kidney Disease
- Mechanism of action in [[Chronic kidney disease|CKD]]
- Key trial results (EMPA-KIDNEY)
- Considerations and side effects
- Contraindications
- Side effects
- Common
- Serious
- Mechanism of action
- History
- Legal status
- Research
- Weight and blood pressure
- Etymology
- 1. Empa- (The Prefix)
- 2. -gli- (The Middle Stem)
- 3. -flozin (The Suffix)
- The Origin of "Phlorizin" (The "Apple" Connection)
- References
Empagliflozin, sold under the brand name Jardiance ( ), among others, is an antidiabetic medication used to improve glucose control in people with type2 diabetes and/or for patients with established heart failure with reduced ejection fraction (HFrEF). Studies have shown great benefits for heart failure (HF) outcomes and decreased hospitalisations. It is taken by mouth.
Common side effects of empagliflozin include genital yeast infections and hypotension, particularly in patients with volume depletion. Other symptoms such as nausea and vomiting may occur and seem more pronounced in combination with metformin. Rare but serious adverse events, such as euglycemic diabetic ketoacidosis (DKA) which may present with hyperventilation, lethargy, or mental status changes have been reported but are infrequent in trials. Other serious but rare serious adverse events include Fournier's gangrene, a severe skin infection of the groin, and diabetic ketoacidosis that may occur even with normal blood glucose levels. Use during pregnancy or breastfeeding is not recommended.
Excerpted from Wikipedia’s “empagliflozin” article, available under the CC BY-SA 4.0 licence.